In summary, NPM1 promotes PCa progression through a c-Myc -mediated pathway via BRD4, and the oncogenic function of NPM1 in PCa can be blocked by the BET inhibitor JQ1 (Fig. 7), indicating that NPM1 may be an effective target for PCa treatment and that blockading the NPM1–c-Myc oncogenic pathway may be a therapeutic strategy for PCa. Here, MYC is linked to posterior cortical atrophy.